The explosion of new information on Helicobacter pylori-related disease, both in the basic sciences and in clinical medicine, has continued to progress at an unprecedented pace. In many instances H. pylori infection, both in man and in the laboratory animal, has become a model to investigate fundamental biological issues such as micro-organism host interactions, intracellular signaling, development of mucosal atrophy, mechanism of microbial resistance, disease modifying factors etc. In view of this bewildering flood of new information, another meeting on H. pylori in the successful series Basic mechanisms to clinical cure' was organized in January 1998 in San Diego, California, to define the state-of-affairs' in H. pylori research at this time. The main objective was to integrate this new information in a series of top-quality presentations and discussions between investigators and clinicians addressing all aspects of H. pylori research and to review the current position and future research directions. The format included state-of-the-art presentations by world experts heavily involved in H. pylori research followed by in-depth discussion on intriguing or controversial issues. The presentations were grouped according to the leading theme: characteristics of the organism, mode of transmission, mechanisms of H. pylori-induced inflammation, causation of disturbances of gastric secretory and motor function, aspects of clinical presentation and management, problems related to H. pylori-associated gastric adenocarcinoma and MALT-lymphoma, novel aspects of antimicrobial therapy and vaccination. The meeting concluded with a synoptic agenda of suggested future studies for the microbiologist, the histopathologist and the clinician. The chapters published in these proceedings accurately reflect the content of the superb presentations. The reader will readily appreciate the excellent level of the cutting-edge' research which was described and discussed. These proceedings are another testimony to the enormous impact on basic science and clinical medicine of the H. pylori discovery. Although much was achieved, it is also readily apparent that many questions remain to be answered and many problems remain to be solved.

Helicobacter pylori has attracted widening interest from basic scientists and clinical investigators and the information on this organism is increasing exponentially. It is now accepted that H. Pylori is the most important cause of chronic active gastritis. Furthermore, data have confirmed a marked reduction in the relapse rate of both duodenal and gastric ulcer after eradication of the organism. These important clinical observations have served as a strong stimulus to the investigation of the basic mechanisms involved in the pathogenesis of H. pylori-associated inflammation and the subsequent alterations of gastroduodenal function and gastric mucosal architecture. The book contains chapters by a multidisciplinary, international group of basic scientists and clinical investigators who focus on various microbiological aspects of H. pylori, on the role of H. pylori in peptic ulcer and gastric cancer, and the current status of therapy. The book contains the proceedings of the conference on `Helicobacter pylori: Basic Mechanisms to Clinical Cure', held at Amelia Island, Florida, U.S.A., on November 3--6, 1993.

IS CROHN'S DISEASE A MYCOBACTERIAL DISEASE'! The fact that the differential diagnosis of inflammatory bowel disease includes intestinal infections has been a source of much interest and clinical concern for many years. Since the recognition of ulcerative colitis and Crohn's disease as clinical entities, numerous attempts have been made to identify a specific organism resulting in the clinical and pathologic picture of Inflammatory Bowel Disease. The first suggestion about a connection between Johne's disease, a chronic mycobacterial enteritis in cattle, and Crohn' s disease occurred in 1913, when Dalziel described enteritis in humans which, although resembling intestinal tuberculosis, he believed to be a new disorder. Since the work of Crohn in the thirties a few investigators attempted to look for mycobacteria in Crohn's disease. Until now the work of Van Patter, Burnham and others did not receive widespread recognition. In 1984 the isolation of M. paratuberculosis was reported by Chiodini et al. This report initiated the current interest and controversy about a mycobacterial etiology in Crohn's disease. The hypothesis "Crohn's disease is Johne's disease" did not receive widespread recognition, but has lead to the first muIticentered efforts to determine whether or not mycobacteria are associated with Crohn's disease.

The impact of Helicobacter pylori on basic science and the clinical management of patients with the complications of this infection is bewildering. The explosion of new information both in the laboratory and at the bedside has progressed at an unprecedented rate. Our main objective in furthering this progress has been to integrate this new information and organize a series of top-quality presentations and discussions between investigators and clinicians on all aspects of H. pylori research and to review the current position and future research directions. To that end, the second meeting 'Helicobacter pylori: Basic Mechanisms to Clinical Cure' was organized in June 1996 in Ottawa, Canada, following the successful format of the first such meeting held in Amelia Island, Florida, in 1993. The meeting again focused on all timely aspects of H. pylori research. Internationally renowned basic and clinical scientists, all experts in their respective fields, explored in depth the spectrum of H. pylori infection and the related complications of gastritis, peptic ulcer, gastric cancer and lymphoma.

H. pylori infection, both in man and in the laboratory animal, has become a standard model to investigate fundamental problems in biology, such as microbial-host interactions, intracellular signalling, modulation of inflammation, mucosal atrophic metaplasia, and microbial resistance, to name just a few. The issues addressed in this book are grouped according to their leading theme. Topics include: the new Helicobacters, strain differences of H. pylori and their consequence on microbial-host interactions and the effects of H. pylori infection on the gastric mucosa. The role of H. pylori is explained in relation to: gastric carcinogenesis; gastroesophageal reflux disease; dyspepsia and long-term acid suppression. Eradication therapies are reviewed with respect to their global consequences and problems. The last two sections are devoted to a global update on therapeutic indications and finally on priorities for further research.
These proceedings accurately reflect the state-of-the-art presentations delivered by world experts. This latest volume will further enrich this top-class series on H. pylori infection.

The fifth meeting in the successful series Helicobacter pylori: Basic Mechanisms to Clinical Cure took place in Maui, Hawaii, November 2002. The meeting focused on all current aspects of H. pylori research. Internationally acclaimed basic and clinical researchers explored, in depth, the novel information across the spectrum of H. pylori infection, the characteristics of the organism, the inflammatory and tissue modifying consequences, the overall impact of this infection on a global scale, and new therapeutic possibilities.
H. pylori infection, both in man and in the laboratory animal, has become a standard model to investigate fundamental problems in biology, such as microbial-host interactions, intracellular signalling, modulation of inflammation, mucosal atrophic metaplasia, and microbial resistance, to name just a few. The issues addressed in this book are grouped according to their leading theme. Topics include: the new Helicobacters, strain differences of H. pylori and their consequence on microbial-host interactions and the effects of H. pylori infection on the gastric mucosa. The role of H. pylori is explained in relation to: gastric carcinogenesis; gastroesophageal reflux disease; dyspepsia and long-term acid suppression. Eradication therapies are reviewed with respect to their global consequences and problems. The last two sections are devoted to a global update on therapeutic indications and finally on priorities for further research.
These proceedings accurately reflect the state-of-the-art presentations delivered by world experts. This latest volume will further enrich this top-class series on H. pylori infection.

Ulcerative colitis and Crohn's disease remain a great therapeutic challenge to the medical community. In recent years knowledge about the pathogenesis of these diseases has progressed rapidly but the cause of the diseases remains completely unknown. It has become clear that dysregulation of the mucosal immune system is the basis for the chronic evolution of the diseases in a genetically susceptible population. Exciting new therapeutic approaches have been attempted in the last couple of years and cytokine and anti-cytokine treatments in particular seem very promising, especially in intractable disease. The format of the Falk Symposium 106 on Advances in Inflammatory Bowel Diseases', held in Brussels, Belgium, June 18-20, 1998, was somewhat innovative as each session attempted to link the new insights into pathogenetic mechanisms with new therapeutic approaches, resulting in optimal information transfer. The classic therapeutic schemes were updated with a special focus on step-wise build-up of therapy.

Endoscopy has revolutionized clinical gastroenterology. In 1961 Basil Hirschowitz published the first flexible endoscopic examination of the stomach and duodenal bulb. We moved from flexible fiberendoscopes to current video-endoscopic equip ment. Current video-endoscopes incorporate a black and white or color 'chip' at the tip of the instrument which transforms the visual image into electronic signals. The size of the pincet is constantly getting smaller, heading for 5 /Lm, further increasing the resolution. The signals are reassembled into high-quality color images in a video monitor. Endoscopes are now used to examine the entire gastrointestinal tract from esophagus to rectum, including the biliary and pancreatic ductal system. Targeted endoscopic biopsy offers rapid and precise diagnosis. Endoscopic ultrasonography is of unsurpassed accuracy in staging gastrointestinal tumors, in assessing pancreatic and biliary disease, and disorders of the rectum and anal canal. Moreover, targeted cytological sampling is possible of abnormalities of the intestinal wall or peri intestinal lymph node. Yet despite these glamorous achievements changes are to be expected in the overall emphasis of diagnostic endoscopy. Magnetic resonance cholangiopancreatography may very well compete for a substantial fraction of diagnostic ERCP. Virtual colonoscopy or computed tomographic colography may well compete with (and take over?) screening/surveillance colonoscopy."

The impact of Helicobacter pylori on basic science and the clinical management of patients with the complications of this infection is bewildering. The explosion of new information both in the laboratory and at the bedside has progressed at an unprecedented rate. Our main objective in furthering this progress has been to integrate this new information and organize a series of top quality presentations and discussions between investigators and clinicians on all aspects of H. pylori research and to review the current position and future research directions. To that end, the second meeting Helicobacter pylori: Basic Mechanisms to Clinical Cure was organized in June 1996 in Ottawa, Canada, following the successful format of the first such meeting held in Amelia Island, Florida, in 1993. The meeting again focused on all timely aspects of H. pylori research. Internationally renowned basic and clinical scientists, all experts in their respective fields, explored in depth the spectrum of H. pylori infection and the related complications of gastritis, peptic ulcer, gastric cancer and lymphoma. The presentations covered: the genetic heterogeneity of the organism, including the expression of virulence factors determined by the genetic pathogenicity island; the intricate cascade of chemokines and cytokines leading to mucosal inflammation; the complexities of the mucosal immune response, favoring a slight Th1 over Th2 lymphocyte imbalance; the fundamental issue of the apparent paradox of the induction of both apoptosis and epithelial hyperproliferation; the pathophysiological consequences of gastric mucosal inflammation with respect to the elevation of gastrin and the acid secretory response; themechanisms leading to peptic ulcer disease, gastric carcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma; the established and novel therapeutic approaches to eradication and finally the prospects for successful therapeutic and preventative vaccination. The comprehensive manuscripts in this book of the proceedings of the meeting reflect the most up-to-date information and state of the art approaches to research and management of H. pylori infection and will provide an invaluable reference source.

There is currently an explosive growth of basic and clinical research in inflammatory bowel diseases. The extensive interest of the medical community in these diseases is largely explained by the devastating impact the illnesses have on the quality of life, their high prevalence in the community, and the fact that so many medical disciplines are involved in tackling the immensely complex studies on pathogenesis, clinical expression and treatment possibilities. The Falk Symposium No. 85 held in The Hague, the Netherlands, 29 June-1 July 1995 brought together over 80 speakers and 1000 participants from all over the world. Plenary sessions and workshops allowed the discussion of basic and clinical research, enabling appropriate choices to be made. Topics reflected areas of high current basic research interest, clinical importance, and actual or future treatment potential. Audience: An important work for all disciplines involved in research and therapy of inflammatory bowel diseases.

International researchers summarize the current understanding of peptic disease and trace the development of a novel new drug for peptic disease therapy-sucralfate. Contributors present laboratory research along side data from clinical trials as well as from the practice of medicine. Articles discuss the history of sucralfate's development, mechanisms of action, clinical efficacy, and future directions for research. This volume will be of interest to scientists and clinicians working in gastroenterology and gastrointestinal physiology.

IS CROHN'S DISEASE A MYCOBACTERIAL DISEASE'! The fact that the differential diagnosis of inflammatory bowel disease includes intestinal infections has been a source of much interest and clinical concern for many years. Since the recognition of ulcerative colitis and Crohn's disease as clinical entities, numerous attempts have been made to identify a specific organism resulting in the clinical and pathologic picture of Inflammatory Bowel Disease. The first suggestion about a connection between Johne's disease, a chronic mycobacterial enteritis in cattle, and Crohn' s disease occurred in 1913, when Dalziel described enteritis in humans which, although resembling intestinal tuberculosis, he believed to be a new disorder. Since the work of Crohn in the thirties a few investigators attempted to look for mycobacteria in Crohn's disease. Until now the work of Van Patter, Burnham and others did not receive widespread recognition. In 1984 the isolation of M. paratuberculosis was reported by Chiodini et al. This report initiated the current interest and controversy about a mycobacterial etiology in Crohn's disease. The hypothesis "Crohn's disease is Johne's disease" did not receive widespread recognition, but has lead to the first muIticentered efforts to determine whether or not mycobacteria are associated with Crohn's disease.

International researchers summarize the current understanding of peptic disease and trace the development of a novel new drug for peptic disease therapy-sucralfate. Contributors present laboratory research along side data from clinical trials as well as from the practice of medicine. Articles discuss the history of sucralfate's development, mechanisms of action, clinical efficacy, and future directions for research. This volume will be of interest to scientists and clinicians working in gastroenterology and gastrointestinal physiology.

Endoscopy has revolutionized clinical gastroenterology. In 1961 Basil Hirschowitz published the first flexible endoscopic examination of the stomach and duodenal bulb. We moved from flexible fiberendoscopes to current video-endoscopic equip ment. Current video-endoscopes incorporate a black and white or color 'chip' at the tip of the instrument which transforms the visual image into electronic signals. The size of the pincet is constantly getting smaller, heading for 5 /Lm, further increasing the resolution. The signals are reassembled into high-quality color images in a video monitor. Endoscopes are now used to examine the entire gastrointestinal tract from esophagus to rectum, including the biliary and pancreatic ductal system. Targeted endoscopic biopsy offers rapid and precise diagnosis. Endoscopic ultrasonography is of unsurpassed accuracy in staging gastrointestinal tumors, in assessing pancreatic and biliary disease, and disorders of the rectum and anal canal. Moreover, targeted cytological sampling is possible of abnormalities of the intestinal wall or peri intestinal lymph node. Yet despite these glamorous achievements changes are to be expected in the overall emphasis of diagnostic endoscopy. Magnetic resonance cholangiopancreatography may very well compete for a substantial fraction of diagnostic ERCP. Virtual colonoscopy or computed tomographic colography may well compete with (and take over?) screening/surveillance colonoscopy.

John Libbey Eurotext continues to publish the proceedings of the gastroenterology seminars taught by leading European specialists and organised by the European Association for Gastroenterology and Endoscopy (EAGE). The aim of the book is to describe major clinical and therapeutic progress observed during 2003.

The fourth meeting in the very successful series Helicobacter pylori: Basic Mechanisms to Clinical Cure was held on the island of Bermuda in late March 2000. This was only some two years after the third meeting in San Diego and it seemed hardly possible that there would be so much new information. However, as the contributions in this volume testify, there was plenty of exciting new information with important implications for both understanding this infection and for clinical management. Some of this information was of a fundamental nature, such as the role of the acid sensitive urel channel in regulating the influx of urea and the formation of ammonia transported back in the microbial periplasmic space to neutralize acid; the observation of genetic polymorphism of the IL-1 gene as an explanation of achlorhydria and gastric cancer risk in the first-degree relatives of gastric cancer patients; and the peculiar biochemical and physio logical consequences of the genome of the microorganisms. The format of the meeting, with short fifteen-minute state-of-the-art pre sentations by world experts closely involved in Helicobacter research fol lowed by ample time for panel discussions, was again followed this year. Traditional aspects included detailed study of the microbial characteristics, the novel Helicobacters, the interaction with the human host, the peculiarities of the inflammatory immune response, the short and long-term mucosal consequences, the effects on acid secretion, the problem of gastric malignancy and the therapeutic possibilities."

The fourth meeting in the very successful series Helicobacter pylori: Basic Mechanisms to Clinical Cure was held on the island of Bermuda in late March 2000 and was sponsored by Axcan Pharma. This was only some two years after the third meeting in San Diego, and it seemed hardly possible that there would be so much new information. However, as the contributions in this volume testify, there was plenty of exciting new information with important implications for both understanding this infection and for clinical management. Some of this information was of a fundamental nature, such as the role of the acid sensitive ureI channel in regulating the influx of urea and the formation of transported ammonia back in the microbial perisplasmic space to neutralize acid; the observation of genetic polymorphism of the IL-1beta gene as an explanation of achlorhydria and gastric cancer risk in the first-degree relatives of gastric cancer patients; and the peculiar biochemical and physiological consequences of the genome of the microorganisms. The format of the meeting, with short fifteen-minute state-of-the-art presentations by world experts closely involved in Helicobacter research followed by ample time for panel discussions, was again followed this year. Traditional aspects included detailed study of the microbial characteristics, the novel Helicobacters, the interaction with the human host, the peculiarities of the inflammatory immune response, the short and long-term mucosal consequences, the effects on acid secretion, the problem of gastric malignancy, and the therapeutic possibilities. However, a series of short debates was introduced to highlight controversial issues, such as the pathogenic orcommensal role of the organism, the role of virulence factors, the characteristics of the inflammatory immune response, the reversibility of mucosal atrophy and metaplasia, and the primary or secondary role of quadruple therapy, to name just a few. This provocative approach was very successful and provided fuel for further in-depth discussions. These debates have been included in this book in the form of conventional manuscripts in order to maintain the shortest possible production time for the publication of the proceedings. Helicobacter pylori has come a long way since the first meeting in Amelia Island, in 1993, and the science of this organism and the understanding of the consequences of the infection have advanced our knowledge fundamentally and revolutionized our thinking about gastrointestinal disease. We now recognize the existence of more than thirty Helicobacter species, some of which may play a significant role in human disease. The experience gained through our investigation of H. pylori promises to make a significant contribution to the future exploration of the possible role of Helicobacter species in hepatic, biliary, and intestinal diseases.